[Skip to Navigation]
Comment & Response
July 11, 2022

Hepatitis C Virus Treatment Delivered via Telemedicine to Persons With Opioid Use Disorder

Author Affiliations
  • 1Jacobs School of Medicine and Biomedical Sciences, State University of New York, Buffalo
  • 2Duke University Medical Center, Durham, North Carolina
  • 3START Treatment & Recovery Centers, Brooklyn, New York
JAMA Intern Med. 2022;182(9):1011. doi:10.1001/jamainternmed.2022.2566

To the Editor We read with interest the editorial by Drs Choudhury and Katz titled “Curing Hepatitis C—Requires More Than a Prescription”1 written in response to the recent publication by Eckhardt and colleagues.2 We agree that all medical care should be delivered in destigmatized, comfortable environments and should seek to be patient centered. We agree that hepatitis C virus (HCV) treatment should be delivered in destigmatizing and supportive environments to people with opioid use disorder (OUD). An important question, as Drs Choudhury and Katz inquired, is whether the model is replicable.1 More broadly, how can vulnerable populations, such as people with OUD, receive improved health care access? One approach, such as that evaluated by Eckhardt and colleagues,2 is to physically co-locate medical treatment for HCV in venues that deliver services to people with OUD. Innovative applications of telemedicine provide alternative approaches to expand supportive, nonjudgmental health care delivery to people with OUD.3

Add or change institution